12-Mar-2020 - CureVac AG

Company Founder Ingmar Hoerr Succeeds Daniel Menichella as CEO of CureVac AG

CureVac AG announced that company founder and Chairman of the Supervisory Board Ingmar Hoerr is replacing Daniel Menichella in his function as Chief Executive Officer (CEO).

"On behalf of the Supervisory Board I would like to thank Dan Menichella very much for the great contributions he has done for CureVac in recent years," said founder and incoming CEO Ingmar Hoerr. "He started as Chief Business Officer of CureVac AG and CEO of CureVac’s US subsidiary, prior to his appointment as Chief Executive Officer in 2018. Dan has been developing our business and advancing important product candidates including our phase 1 rabies program CV 7202, our phase 1 immuno oncology therapy trial CV 8102 and the recent start of our Coronavirus vaccine program. He was also largely responsible for the cooperation agreements with Eli Lilly, CRISPR Therapeutics and the Danish biotech company Genmab.” I want to thank Dan for his leadership having built a terrific global team.

Hoerr also said: “CureVac has a great team, extraordinary expertise and huge potential. Together, we will continue to focus fully on taking the company to the next stage of its development and advance our clinical product pipeline with the goal of bringing mRNA-based drugs to patients. The vaccine against Covid-19 plays a key role here.”

"As a Founding-CEO, scientist and visionary Ingmar Hoerr knows the company best and is the right person to lead CureVac into the future," said Jean Stéphenne, deputy Chairman of the Supervisory Board. "We are convinced that he and his team will succeed in developing important mRNA therapeutics and vaccines, such as those against the coronavirus."

Facts, background information, dossiers
  • CureVac
  • personnel changes
More about CureVac
  • News

    CureVac's coronavirus vaccine candidate shows positive pre-clinical results at low dose

    CureVac AG announced positive pre-clinical results at a low dose for its lead vaccine candidate against the novel Coronavirus (SARS-CoV-2). The data showed a fast induction of a balanced immune response with high levels of virus neutralizing titers (VNTs) and T-cell responses. VNTs are a ma ... more

    CureVac rejects current rumors of an acquisition

    CureVac AG confirmed that internal efforts are focused on the development of a coronavirus vaccine with the goal to reach, help and to protect people and patients worldwide. As a consequence, the company is in contact with especially CEPI and many other organizations and authorities worldwi ... more

    CureVac Enters into an Exclusive Collaborative Research Agreement with Yale University

    CureVac AG announced it has entered into a Collaborative Research Agreement (“CRA”) with Yale University for discovery research into mRNA-based pulmonary therapeutic candidates.  The exclusive CRA covers the development of an undisclosed number of novel mRNA-based candidates for pulmonary d ... more

  • Companies

    CureVac AG

    CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 18 years’ expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the hum ... more